Lupin Ltd.

NSE: LUPIN | BSE: 500257 | ISIN: INE326A01037 | Industry: Pharmaceuticals
| Falling Comet
1995.2000 51.20 (2.63%)
NSE Jun 05, 2025 15:59 PM
Volume: 1.1M
 

logo
Lupin Ltd.
10 Jul 2024
1995.20
2.63%
ICICI Securities Limited
Lupin’s recent success in US (sales grew ~34% YoY in FY24) is driven by its better regulatory track record and traction in inhalation portfolio. Share of inhalation products has risen from 25% of US sales in FY22 (USD 185mn) to 40% in FY24
(USD 326mn) post the launch of gSpiriva. In India, growth had been subdued due to the discontinuation of in-licensed brands (contribution down from 15% in FY23 to 11% in Q4FY24).
Lupin Ltd. has an average target of 2343.89 from 9 brokers.
More from Lupin Ltd.
Recommended